News

AqT Biotinylated Secondary Antibodies CellMosaic® has launched AqT® biotinylated secondary antibodies this October, expanding our Aq

Building on our site-specific antibody-drug conjugation (ADC) technologies, CellMosaic® is launching an AqueaTether®-enabled antibod

Exciting News! We are thrilled to announce that our patent application has been granted by the Brazilian Patent Office! The granted patent,

Congratulations to the Research Teams We applaud the collaborative work of researchers from the University of New Mexico (UNM), Duke Univers

At CellMosaic®, we are committed to advancing scientific research by providing innovative bioconjugates that empower scientists to drive

At CellMosaic®, we’re committed to empowering researchers with high-quality, innovative, and advanced bioconjugates—making c

CellMosaic is proud to introduce three new maleimide-activated protein carrier products for immunization and diagnostic applications. Design

Partnership Spotlight: The Urgent Need for Opioid Treatment Every 7 minutes, someone in America loses their life to an opioid overdose. Whil

Exciting news! The USPTO has just granted our latest patent for branched high-loading AqueaTether® linker technologies. This technology

Breaking Ground: A New Patent for Better Medicine Innovation in biotech often starts with a document that represents years of research. Her

We are excited to announce the addition of two unique PerKit® products to our website this week! These products were developed in respon